Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

MDA-TIL

Cell therapy (Tumor-infiltrating lymphocytes) · Kills target cells, directed at tumor cells

Phase 2 Most advanced trial (none active)
1 Registered trials

What is MDA-TIL?

MDA-TIL is an autologous tumor infiltrating lymphocyte (TIL) therapy. Patient TILs are isolated from tumor tissue, expanded in vitro with IL-2 and anti-4-1BB stimulation, then reinfused to recognize and kill the patient's tumor cells. It is studied in metastatic colorectal and ovarian cancers, and pancreatic cancer.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Cell therapy (Tumor-infiltrating lymphocytes)
Targets
tumor cells (antigen)
Mechanism
Kills target cells, directed at tumor cells
Therapy area
Oncology
In trials of
IOVA
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT03610490 Phase 2 Malignant Solid Neoplasm Terminated IOVA

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Malignant Solid NeoplasmMetastatic Colorectal AdenocarcinomaMetastatic Ovarian CarcinomaMetastatic Pancreatic Ductal AdenocarcinomaPlatinum-Resistant Ovarian CarcinomaRecurrent High Grade Ovarian Serous AdenocarcinomaRecurrent Ovarian CarcinosarcomaRefractory Colorectal CarcinomaStage IV Colorectal Cancer AJCC v8Stage IVA Colorectal Cancer AJCC v8Stage IVB Colorectal Cancer AJCC v8Stage IVC Colorectal Cancer AJCC v8

Sources

Updated Oct 3, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.